Daniel ZAGURY

POPULATION OF TREG CELLS FUNCTIONALLY COMMITTED TO EXERT A REGULATORY ACTIVITY AND THEIR USE FOR ADOPTIVE THERAPY

EX VIVO GENERATION OF GAMMA DELTA FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF

USE OF CD26 AND CD39 AS NEW PHENOTYPIC MARKERS FOR ASSESSING MATURATION OF FOXP3+ T CELLS AND USES THEREOF FOR DIAGNOSTIC PURPOSES

Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART

Vaccine to pathogenic immune activation cells during infections

Vaccine to pathogenic immune activation cells during infections

Vaccine to pathogenic immune activation cells during infections

IMMUNOTHERAPEUTIC USES OF EX VIVO GENERATED FOXP3+ REGULATORY T CELLS

Ex vivo generation of γδ Foxp3regulatory T cells and therapeutic uses thereof

Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof

Stable immunogenic product comprising antigenic heterocomplexes

Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein

Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors

High-yield method for the production of human antibodies blocking the biological activity of a human cytokine

Method for monitoring anti-HIV treatment in HIV infected individuals

Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus

Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's

Method for determining prognosis of HIV infected individuals

Stable immunogenic product comprising antigenic heterocomplexes

Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's

Method for preparing a stable TNF-α vaccine

Chemically modified cytokines

Chemically modified TNF-α